文献速递肺血管病与心包/心肌炎瓣膜病与结构性心脏病

经皮肺动脉成形术治疗大动脉炎相关肺动脉高压

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

这项前瞻性队列研究纳入50例完成经皮肺动脉成形术(PTPA)的大动脉炎相关肺动脉高压(TA-PH)患者和21例拒绝手术的患者,平均随访37±14个月,PTPA组3年生存率93.7%,非PTPA组76.2%(P=0.0096),PTPA与全因死亡风险降低相关(HR 0.18,95%CI 0.05-0.73,P=0.017),安全性可接受。

要点

  • PTPA与TA-PH患者全因死亡风险显著降低相关(HR 0.18)。
  • PTPA组3年生存率93.7%,非PTPA组76.2%。
  • 严重并发症需无创正压通气者仅占0.7%(1/150次操作)。

核心结论

  • PTPA倾向于降低TA-PH患者全因死亡风险,安全性可接受,可能是有前景的治疗选择。

主要发现

  • 平均随访37±14个月,PTPA组死亡3例(6.0%),非PTPA组死亡6例(28.6%)。
  • 3年生存率PTPA组93.7%,非PTPA组76.2%(log-rank P=0.0096)。
  • Cox回归显示PTPA与全因死亡风险降低相关(HR 0.18;95%CI 0.05-0.73;P=0.017)。
  • 围术期无死亡,150次操作中仅1次(0.7%)出现需无创正压通气的严重并发症。

临床怎么用

  • 对于TA-PH患者,PTPA可作为考虑的治疗选项,需评估操作相关并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous transluminal pulmonary angioplasty (PTPA) is a treatment modality for chronic thromboembolic pulmonary hypertension, but whether it can be applied to Takayasu arteritis-associated pulmonary hypertension (TA-PH), another chronic obstructive pulmonary vascular disease, remains unclear. OBJECTIVES: This study sought to investigate the efficacy and safety of PTPA for TA-PH. METHODS: Between January 1, 2016, and December 31, 2019, a total of 50 patients with TA-PH who completed the PTPA procedure (the PTPA group) and 21 patients who refused the PTPA procedure (the non-PTPA group) were prospectively enrolled in this cohort study. The primary outcome was all-cause mortality. The safety outcomes included PTPA procedure-related complications. RESULTS: Baseline characteristics and medical therapies were similar between the PTPA group and the non-PTPA group. During a mean follow-up time of 37 ± 14 months, deaths occurred in 3 patients (6.0%) in the PTPA group and 6 patients (28.6%) in the non-PTPA group, contributing to the 3-year survival rate of 93.7% in the PTPA group and 76.2% in the non-PTPA group (P = 0.0096 for log-rank test). The Cox regression model showed that PTPA was associated with a significantly reduced hazard of all-cause mortality in TA-PH patients (HR: 0.18; 95% CI: 0.05-0.73; P = 0.017). No periprocedural death occurred. Severe complications requiring noninvasive positive pressure ventilation occurred in only 1 of 150 total sessions (0.7%). CONCLUSIONS: PTPA tended to be associated with a reduced risk of all-cause mortality with acceptable safety profiles and seemed to be a promising therapeutic option for TA-PH patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zhou YP, Wei YP, Yang YJ, et al. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022. PMID: 35422244. doi:10.1016/j.jacc.2022.01.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。